About NovaQuest Capital Management
NovaQuest Capital Management is a private equity firm founded in 2000. It is primarily based in Raleigh, United States. As of Oct 2026, NovaQuest Capital Management is an active investor with a portfolio of 37 companies, comprising 37 funding rounds and 8 acquisitions. In the last 12 months, it has participated in 1 funding round. The firm primarily invests in companies based in United States and United Kingdom. Its portfolio is spread across a wide range of sectors from Life Sciences to Healthcare. Its latest investment was a $***** Series A round in MI:RNA Diagnostics on Dec 10, 2025
Overall NovaQuest Capital Management portfolio has seen 11 IPOs and 14 acquisitions, namely Lilly, Revance Therapeutics and Roivant Sciences. A lot of funds co-invest with NovaQuest Capital Management, with names like Quintiles sharing a substantial percentage of its portfolio.
NovaQuest Capital Management has a team of 10 people, including 5 partners.
Key Metrics
Founded Year
2000
Location
Raleigh, United States
Portfolio Companies
Portfolio Sectors
Portfolio Locations
Investment Deals
NovaQuest Capital Management's Portfolio
NovaQuest Capital Management has a portfolio of 37 companies. They have invested in a total of 37 companies. Their most recent investment was in MI:RNA Diagnostics (Series A round) on Dec 10, 2025. Here are the most recent investments by NovaQuest Capital Management:Date | Company | Round | Amount | Co-Investors |
|---|---|---|---|---|
Dec 10, 2025 | Series A | 1485 | - | |
Jun 27, 2025 | Series B | 7799 | ||
Jun 28, 2024 | Series A | 2779 | ||
Oct 14, 2022 | Seed | 9377 | - |
NovaQuest Capital Management has acquired 8 companies. Their most recent acquisition was of Lexitas on Jul 19, 2022. Here are the most recent acquisitions by NovaQuest Capital Management:
Acquisition Date | Company | Short Description | Total Funding | Founded Year |
|---|---|---|---|---|
Jul 19, 2022 | Provider of legal services | - | 1987 | |
Jan 19, 2021 | CDMO with a focus on early phase drug product development | $15M | 2006 | |
Aug 04, 2020 | Clinical trial solutions provider specializing in eSource technology and patient-centric research | $14.8M | 2006 | |
Jan 20, 2026 | Full-service clinical research organization | - | 2013 |
Here is the portfolio snapshot of NovaQuest Capital Management:
Investments by Year
The maximum number of investments were made in 2020
Acquisitions by Year
The maximum number of acquisitions were made in 2018
Portfolio by Location
Companies are primarily in United States and United Kingdom
Portfolio by Sector
Companies are primarily in Life Sciences
Team profile of NovaQuest Capital Management
NovaQuest Capital Management has a team of 10 members including 5 Partners and 1 Principal located in United States. NovaQuest Capital Management's team does not sit on the board of any company as of now.Here is a list of all team members in NovaQuest Capital Management:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Raleigh | - | - | |
Partner | Raleigh | - | - | |
Partner | Raleigh | - | - | |
Partner | Raleigh | - | - | |
Partner | United States | - | - | |
Principal | Durham | - | - | |
Associate | Raleigh | - | ||
Associate | Raleigh | - | - | |
Associate | Raleigh | - | - | |
Associate | Raleigh | - | - |
Co-investors of NovaQuest Capital Management
Over the past 26 years, 41 investors have co-invested in NovaQuest Capital Management's portfolio companies.
- Top Co-investors of NovaQuest Capital Management: 41 investors entered a company along with NovaQuest Capital Management. These include investors like Quintiles (1 company).
NovaQuest Capital Management News
•
Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit LineBenzinga•Dec 30, 2025•Oaktree Capital Management, NovaQuest Capital Management, Mesoblast
•
MI:RNA Secures $3.6M Funding to Advance Veterinary DiagnosticsScottish Business News•Dec 10, 2025•MI:RNA Diagnostics, Scottish Enterprise, NovaQuest Capital Management, Kyoritsu Seiyaku and 1 other
•
Gallant Secures $18M Series B for Ready-to-Use Pet Stem Cell Therapiesintelligence360•Jul 10, 2025•Gallant, NovaQuest Capital Management, Bold Capital Partners, Digitalis Ventures and 1 other
•
Gallant Secures $18M for FDA-Approved Stem Cell Therapy in Veterinary MedicineTechCrunch+•Jul 05, 2025•Gallant, NovaQuest Capital Management, Digitalis Ventures
•
Veterinary diagnostics spin-out raises $4 millionInsider•Jul 03, 2024•NovaQuest Capital Management, Kyoritsu Seiyaku, Animal Health Angels, Equity Gap and 5 others
•
Raleigh capital management firm NovaQuest looks to raise $800MWRAL TechWire•Jun 28, 2023•NovaQuest Capital Management
•
FibroGen’s Royalty Monetization Financing with NovaQuest Capital ManagementGlobal Legal Chronicle•Nov 10, 2022•FibroGen, NovaQuest Capital Management, Goodwin
•
Monroe Capital Supports QHP Capital’s Acquisition of AutoCruitmentBusiness Wire•Nov 01, 2022•Monroe Capital, AutoCruitment, QHP Capital, NovaQuest Capital Management
•
NovaQuest Private Equity rebrands as QHP CapitalPrivate Equity Wire•Oct 21, 2022•NovaQuest Capital Management
•
Idera Pharmaceuticals completes acquisition of AceragenSeeking Alpha•Sep 29, 2022•Aceragen, NovaQuest Capital Management
